Trial Information

Summary: Lupus – SLE (SYSTEMIC LUPUS ERYTHEMATOSUS) - Adults

People with SLE (SYSTEMIC LUPUS ERYTHEMATOSUS ) are asked to participate in a research study being conducted by Feinstein Institute for Medical Research.

You may be eligible to participate in this study if you:

• Are at least 18 years of age
• Have been diagnosed with SLE

You may not participate in this study if you:

• Have received the study drug MEDI-545 within 120 days prior to screening
• If you weigh equal to or less than 54.5 lbs (120 kg)
• Have received prednisone greater than 20 mg/day (or an equivalent dose of another oral corticosteroid) within 14 days before entry into the study
• Have received the following dosages of medication prior to entry to the study: hydroxychloroquine greater than 600mg/day, mycophenolate mofetil greater than 3g/day, methotrexate greater than 25 mg/week, leflunomide greater than 20 mg/day, azathioprine greater than 3mg/kg/day or any dose of dapsone, cyclophosphamide, cyclosporine or thalidomide
• Have received doses of antimalarials, mycophenolate mofetil, methotrexate, leflunomide, or azathioprine within 28 prior to study entry
• Have received doses of NSAIDs (Non-steroidal anti-inflammatory drugs) or oral corticosteroids within 14 days prior to study entry
• Have a history of severe viral infections such as herpes or cytomegalovirus
• Evidence of infection with hepatitis B or C or active infection of hepatitis A
• Evidence of infection with HIV-1 or HIV-2
• Have been vaccinated with live attenuated viruses (vaccines) within 21 months before entry into the study
• History of alcohol or drug abuse or history of cancer, less than 1 year prior to study entry
• Are pregnant, breastfeeding, or intend to become pregnant during the study
• Have participated in another research study within the last 30 days

If you would like to learn more about participating in this study, please send an e-mail message using the form below.